Resources
27 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 5/26/2023 (updated 3/27/2024)
More than 450 clinicians and counselors in rural New England were surveyed about stigma as a barrier to treating patients for opioid used disorder (OUD) as well as practitioners’ beliefs about medications for OUD. Over half (55 percent) ranked stigma as the highest barrier among other factors such as time and staffing, medication diversion, and organizational/clinic barriers.
Posted 9/7/2022 (updated 3/27/2024)
During this webinar, Claudia Jasso, Chief Development Officer for RCORP Implementation grantee, Amistades, Inc. and Janet Ojeda, JBS International Technical Expert Lead will present an overview of the unique cultural context, core beliefs, and value systems that should be at the heart of understanding and engaging with Latino populations. Presenters will discuss how racial inequity, assimilation, risk factors, and historical and immigration trauma have created a landscape where there is a critical need for person centered, culturally respectful and relevant mental health and SUD/OUD supports and service delivery for Latino people. All RCORP grantees, consortium members, and key community partners are welcome to attend.
Posted 6/27/2022 (updated 3/27/2024)
Naloxone leave behind programs are a popular public health intervention for combatting the opioid epidemic. These programs are designed for first responders to educate and equip high risk, nonmedical individuals to respond to opioid overdose scenarios. However, stigma and misconceptions regarding naloxone remain common among medical providers, including emergency medical services (EMS) members.
Posted 6/14/2022 (updated 3/27/2024)
Overdose education and naloxone distribution (OEND) to laypersons are key approaches to reduce the incidence of opioid-involved overdoses. While some research has examined attitudes toward OEND, especially among pharmacists and first responders, our understanding of what laypersons believe about overdose and naloxone is surprisingly limited.
Posted 10/27/2021 (updated 4/3/2024)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
The workshop presented strategies to integrate HIV, hepatitis, and sexual health concerns into services for PWID. The session will focus on communication skills, assessment techniques, and building motivation among PWID to make healthier choices. Mr. Sacco looked at programmatic and clinical-level integration strategies and offered participants an opportunity to assess current service delivery models and develop a plan to enhance care. Mrs. Bell and Ms. Chavis intrdoduce participants to resources and funding opportunities available through HRSA’s HIV/AIDS Bureau (HAB).
Posted 9/1/2021 (updated 4/2/2024)
Affinity Group Breakout Sessions: Listed facilitators will briefly present and lead a group discussion on their respective topics.
Posted 8/4/2021 (updated 4/2/2024)